• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过一种新开发的患者工具评估接受铁螯合疗法的铁过载患者的满意度和依从性。

Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument.

作者信息

Rofail Diana, Abetz Linda, Viala Muriel, Gait Claire, Baladi Jean-Francois, Payne Krista

机构信息

Mapi Values, Bollington, Cheshire, UK.

出版信息

Value Health. 2009 Jan-Feb;12(1):109-17. doi: 10.1111/j.1524-4733.2008.00390.x. Epub 2008 Jul 11.

DOI:10.1111/j.1524-4733.2008.00390.x
PMID:18637142
Abstract

OBJECTIVES

This study assesses satisfaction with iron chelation therapy (ICT) based on a reliable and valid instrument, and explores the relationship between satisfaction and adherence to ICT.

METHODS

Patients in the USA and UK completed a new "Satisfaction with ICT" (SICT) instrument consisting of 28 items, three pertaining to adherence. Simple and multivariate regression analyses assessed the relationship between satisfaction with different aspects of ICT and adherence.

RESULTS

First assessments of the SICT instrument indicate its validity and reliability. Recommended thresholds for internal consistency, convergent validity, discriminant validity, and floor and ceiling effects were met. A number of variables were identified in the simple linear regression analyses as significant predictors of "never thinking about stopping ICT," a proxy for adherence. These significant variables were entered into the multivariate model to assess the combined factor effects, explaining 42% of the total variance of "never thinking about stopping ICT." A significant and positive relationship was demonstrated between "never thinking about stopping ICT" and age (P = 0.04), Perceived Effectiveness of ICT (P = 0.003), low Burden of ICT (P = 0.002), and low Side Effects of ICT (P = 0.01).

CONCLUSIONS

The SICT is a reliable and valid instrument which will be useful in ICT clinical trials. Furthermore, the administration of ICT by slow subcutaneous infusion negatively impacts on satisfaction with ICT which was shown to be a determinant of adherence. This points to the need for new more convenient and less burdensome oral iron chelators to increase adherence, and ultimately to improve patient outcomes.

摘要

目的

本研究基于一种可靠且有效的工具评估对铁螯合疗法(ICT)的满意度,并探讨满意度与ICT依从性之间的关系。

方法

美国和英国的患者完成了一项新的“ICT满意度”(SICT)工具,该工具包含28个项目,其中3个与依从性有关。简单和多元回归分析评估了ICT不同方面的满意度与依从性之间的关系。

结果

对SICT工具的首次评估表明其有效性和可靠性。达到了内部一致性、收敛效度、区分效度以及地板效应和天花板效应的推荐阈值。在简单线性回归分析中,确定了一些变量是“从未考虑停止ICT”(依从性指标)的显著预测因素。将这些显著变量纳入多元模型以评估综合因素效应,解释了“从未考虑停止ICT”总方差的42%。“从未考虑停止ICT”与年龄(P = 0.04)、ICT感知有效性(P = 0.003)、ICT低负担(P = 0.002)和ICT低副作用(P = 0.01)之间存在显著正相关。

结论

SICT是一种可靠且有效的工具,将在ICT临床试验中有用。此外,皮下缓慢输注ICT对ICT满意度有负面影响,而满意度被证明是依从性的一个决定因素。这表明需要新的更方便且负担更小的口服铁螯合剂来提高依从性,并最终改善患者结局。

相似文献

1
Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument.通过一种新开发的患者工具评估接受铁螯合疗法的铁过载患者的满意度和依从性。
Value Health. 2009 Jan-Feb;12(1):109-17. doi: 10.1111/j.1524-4733.2008.00390.x. Epub 2008 Jul 11.
2
A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major.一种用于评估β-地中海贫血患者铁螯合治疗(ICT-Sat)满意度的新工具。
Pediatr Blood Cancer. 2012 Jun;58(6):910-5. doi: 10.1002/pbc.23413. Epub 2012 Jan 9.
3
Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.地拉罗司治疗β-地中海贫血铁过载患者的疗效满意度和便利性提高:ESCALATOR 试验结果。
Acta Haematol. 2010;123(4):220-5. doi: 10.1159/000313447. Epub 2010 Apr 27.
4
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.在英国,对需要铁螯合治疗的患者,地拉罗司与去铁胺标准疗法的成本效用分析。
Curr Med Res Opin. 2008 Jun;24(6):1609-21. doi: 10.1185/03007990802077442. Epub 2008 Apr 24.
5
Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.地拉罗司与去铁胺治疗镰状细胞病 Medicaid 患者的坚持性和顺应性。
J Clin Pharm Ther. 2012 Apr;37(2):173-81. doi: 10.1111/j.1365-2710.2011.01276.x. Epub 2011 May 18.
6
A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care settings in Western Greece.在希腊西部常规医疗环境下,对依赖输血的β-地中海贫血症患者的生活质量和铁螯合治疗满意度进行的一项多中心横断面研究。
Qual Life Res. 2021 Feb;30(2):467-477. doi: 10.1007/s11136-020-02634-y. Epub 2020 Sep 13.
7
Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.与去铁胺相比,输血依赖型β地中海贫血患者对地拉罗司(Exjade®)的依从性和满意度。
Hematology. 2014 Jun;19(4):187-91. doi: 10.1179/1607845413Y.0000000121. Epub 2013 Nov 25.
8
[Iron overload and iron chelation therapy].[铁过载与铁螯合疗法]
Rinsho Ketsueki. 2012 Jan;53(1):25-35.
9
Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.铁螯合疗法:铁过载患者的临床疗效、经济负担及生活质量
Adv Ther. 2008 Aug;25(8):725-42. doi: 10.1007/s12325-008-0085-z.
10
[Pathogenesis of transfusional iron overload and iron chelation therapy].[输血性铁过载的发病机制及铁螯合疗法]
Rinsho Ketsueki. 2009 Jul;50(7):527-31.

引用本文的文献

1
Patient-reported outcome measures for medication treatment satisfaction: a systematic review of measure development and measurement properties.患者报告的药物治疗满意度测量指标:测量开发和测量特性的系统评价。
BMC Med. 2024 Sep 2;22(1):347. doi: 10.1186/s12916-024-03560-3.
2
Adherence to Iron Chelation Therapy among Adults with Thalassemia: A Systematic Review.成人地中海贫血患者铁螯合治疗的依从性:系统评价。
Hemoglobin. 2022 Jul;46(4):201-213. doi: 10.1080/03630269.2022.2072320. Epub 2022 Aug 5.
3
Adherence to Iron Chelation Therapy and Its Determinants.
铁螯合疗法的依从性及其决定因素。
Int J Hematol Oncol Stem Cell Res. 2021 Jan 1;15(1):27-34. doi: 10.18502/ijhoscr.v15i1.5247.
4
Measurement Properties of Existing Patient-Reported Outcome Measures on Medication Adherence: Systematic Review.现有药物依从性患者报告结局测量工具的测量特性:系统评价。
J Med Internet Res. 2020 Oct 9;22(10):e19179. doi: 10.2196/19179.
5
Development of an Item Bank to Measure Medication Adherence: Systematic Review.开发用于测量药物依从性的项目库:系统评价。
J Med Internet Res. 2020 Oct 8;22(10):e19089. doi: 10.2196/19089.
6
[Evaluation of satisfaction with pharmacological treatment in people with hypertension].[高血压患者药物治疗满意度评估]
Rev Esp Salud Publica. 2019 Oct 30;93:e201910080.
7
Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy.铁螯合疗法患者及照料者报告结局指标的定性改进与发展
Health Qual Life Outcomes. 2017 Jun 23;15(1):129. doi: 10.1186/s12955-017-0702-0.
8
Adherence and treatment satisfaction in liver transplant recipients.肝移植受者的依从性和治疗满意度。
Saudi J Gastroenterol. 2016 Mar-Apr;22(2):127-32. doi: 10.4103/1319-3767.164209.
9
Assessing the Impact of Caring for a Person with Schizophrenia: Development of the Schizophrenia Caregiver Questionnaire.评估照料精神分裂症患者的影响:精神分裂症照料者问卷的编制
Patient. 2015 Dec;8(6):507-20. doi: 10.1007/s40271-015-0114-3.
10
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial.接受地拉罗司治疗的铁过载β地中海贫血和骨髓增生异常综合征患者的健康相关生活质量、治疗满意度、依从性和持续性:EPIC临床试验结果
Anemia. 2012;2012:297641. doi: 10.1155/2012/297641. Epub 2012 Aug 12.